University of Iowa Hospitals & Clinics
Welcome,         Profile    Billing    Logout  
 272 Trials 
621 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Silverman, Margarida
ARTEMIS, NCT04511130: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Completed
2
47
US
MT-401, zedenoleucel
Marker Therapeutics, Inc.
Acute Myeloid Leukemia, Stem Cell Transplantation
03/24
03/24
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Marsh, J Wallis
NCT01360606: Stereotactic Body Radiation Therapy (SBRT) for Liver Mets

Completed
N/A
9
US
Stereotactic Body Radiation Therapy, CyberKnife, Trilogy, True Beam, Radiosurgery
Susannah Ellsworth
Liver Metastases
07/18
02/21
NCT03809520: An Imaging Framework for Clinically Testing New Treatments to Prevent Post-traumatic OA

Recruiting
N/A
20
US
pedCAT
J L Marsh, Orthopaedic Trauma Association
Orthopedic Disorder, Trauma, Ankle Fractures, Post-traumatic Osteoarthritis
12/24
12/24
PRMRP FPA CT, NCT05209347: Custom Dynamic Orthoses to Reduce Articular Contact Stress

Withdrawn
N/A
20
US
Carbon Fiber Custom Dynamic Orthosis (CDO), Ankle Foot Orthosis (AFO)
University of Iowa
Ankle Fractures, Post-traumatic Osteoarthritis, Osteoarthritis Ankle
12/25
12/25
Russell, Stephen R
NCT00999609 / 2016-002109-20: Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

Checkmark AAPOS 2018
Apr 2018 - Apr 2018: AAPOS 2018
Checkmark For Leber Congenital Amaurosis
Jul 2017 - Jul 2017: For Leber Congenital Amaurosis
Checkmark
More
Active, not recruiting
3
31
US
AAV2-hRPE65v2,voretigene neparvovec-rzyl, AAV2-hRPE65v2, voretigene neparvovec-rzyl, gene therapy vector
Spark Therapeutics, Inc., Children's Hospital of Philadelphia, University of Iowa
Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis
07/15
07/29
NCT04291105: Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Recruiting
2
87
US, RoW
VV1, VSV-IFNβ-NIS, Voyager V1, VV1, Cemiplimab, Libtayo
Vyriad, Inc., Regeneron Pharmaceuticals
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
12/24
03/25
NCT00349739: Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate

No Longer Available
N/A
US
Anecortave Acetate, Retaane
University of Iowa
Macular Degeneration
 
08/08
NCT03602820: Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

Active, not recruiting
N/A
41
NA
AAV2-hRPE65v2, Voretigene Neparvovec-rzyl
Spark Therapeutics
Inherited Retinal Dystrophy Due to RPE65 Mutations
03/30
06/30
Makkar, Raj
PORTICO IDE, NCT02000115: Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

Recruiting
N/A
1150
US, RoW
Portico transcatheter aortic valve, Commercially available transcatheter aortic valve
Abbott Medical Devices
Aortic Valve Stenosis
10/19
07/25
NCT04338347: CAP-1002 in Severe COVID-19 Disease

No Longer Available
N/A
US
CAP-1002 Allogeneic Cardiosphere-Derived Cells
Capricor Inc.
COVID-19
 
 
NCT03904147: TRILUMINATE Pivotal Trial

Active, not recruiting
N/A
572
Europe, Canada, US
TriClipTM Device
Abbott Medical Devices
Tricuspid Regurgitation
11/22
04/29
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
NCT03735667: ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

Active, not recruiting
N/A
1948
Canada, US
ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL
Boston Scientific Corporation
Aortic Stenosis
06/24
09/34
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Recruiting
N/A
958
Canada, US
Tendyne Mitral Valve System, MitraClip System
Abbott Medical Devices
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
05/24
06/28
NCT05061004: Cephea Early Feasibility Study

Recruiting
N/A
50
Canada, US
Cephea Mitral Valve System
Abbott Medical Devices
Mitral Regurgitation
03/26
03/31
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
NCT04433065: TTVR Early Feasibility Study

Recruiting
N/A
15
US
Intrepid™ TTVR System
Medtronic Cardiovascular
Tricuspid Regurgitation
07/25
07/31
RESOLVE, NCT02318342: Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation

Recruiting
N/A
3000
US
Warfarin, Coumadin
Cedars-Sinai Medical Center
Prosthetic Valve Thrombosis
12/25
12/26
MITRAL-II, NCT04408430: The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Recruiting
N/A
210
US
Transseptal ViMAC, ViMAC
Mayra Guerrero
Mitral Annular Calcification, Mitral Stenosis, Mitral Regurgitation, Mitral Valve Disease
12/24
12/24
CLASP II TR, NCT04097145: Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Recruiting
N/A
870
Canada, US
Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
12/27
12/31
ARTIST, NCT06608823: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

Not yet recruiting
N/A
1016
NA
Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System, SAVR
JenaValve Technology, Inc.
Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
02/26
02/36
CHOICE-MI, NCT04688190: CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

Recruiting
N/A
800
Europe, Canada, US, RoW
Universitätsklinikum Hamburg-Eppendorf, Montreal Heart Institute, University Hospital, Bordeaux
Mitral Regurgitation
03/25
12/30
NCT04198870: MitraClip REPAIR MR Study

Recruiting
N/A
500
Europe, Canada, US
MitraClip™ device implantation, Mitral Valve Repair Surgery
Abbott Medical Devices
Mitral Valve Regurgitation
04/26
04/34
BASELINE, NCT04843072: Balloon vs. Self Expanding Transcatheter Valve for Degenerated Bioprosthesis

Recruiting
N/A
400
Europe, Canada, US
Evolut R/PRO bioprosthesis, Edwards Sapien S3/Ultra bioprosthesis
Erasmus Medical Center
Valve Heart Disease
05/26
05/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
NCT05427370: The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

Recruiting
N/A
754
Europe, Canada, US, RoW
Revascularization by PCI, Revascularization by CABG
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR), Weill Medical College of Cornell University
Coronary Artery Disease, Heart Failure Systolic
04/29
12/29
PROGRESS, NCT04889872: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

Recruiting
N/A
2250
Europe, Canada, Japan, US, RoW
SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
Edwards Lifesciences
Aortic Stenosis, Calcific, Aortic Valve Stenosis
06/29
06/37
NCT00573027: Heart Disease of the Small Arteries in Women and Men

Recruiting
N/A
634
US
noninvasive tests
Cedars-Sinai Medical Center
Heart Disease
01/40
01/40
Bender, David P
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NRG-GY026, NCT05256225: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer

Recruiting
2/3
525
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, High-Dose-Rate Vaginal Cuff Brachytherapy, HDR-VCB, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab and Trastuzumab hyaluronidase, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab/Hyaluronidase-oysk, Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20, Trastuzumab-Hyaluronidase-oysk
National Cancer Institute (NCI), NRG Oncology
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Carcinosarcoma
10/27
10/27
NRG-GY029, NCT05295589: Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Withdrawn
2
96
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI), NRG Oncology
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
03/23
03/23
NRG-GY033, NCT06169124: Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Suspended
2
37
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Chest Radiography, Chest X-ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Exemestane, Aromasin, FCE-24304, Leuprolide Acetate, A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI), NRG Oncology
Adult Ovarian Granulosa Cell Tumor
05/27
05/27
NCI-2017-01672, NCT03660826: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Active, not recruiting
2
286
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
12/24
01/26
NRG-GY025, NCT05112601: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Recruiting
2
90
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
04/26
04/26
VB-C-04, NCT06099418: Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Withdrawn
2
130
NA
VB10.16, Atezolizumab Injection [Tecentriq], Placebo
Nykode Therapeutics ASA, Roche Pharma AG, GOG Foundation
HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
05/27
05/28
NRG-GY028, NCT05538897: Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recruiting
1/2
96
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Megestrol Acetate, 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate, 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione, 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone, 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone, BDH 1298, BDH-1298, Maygace, Megace, Megestat, Megestil, Niagestin, Ovaban, Pallace, SC 10363, SC-10363
National Cancer Institute (NCI), NRG Oncology
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
01/27
01/27
NXP800-101, NCT05226507: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

Recruiting
1
61
Europe, US
NXP800
Nuvectis Pharma, Inc., European Network for Gynaecological Oncological Trial Groups, Gynecologic Oncology Group Foundation
Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
05/25
12/25
NRG-GY031, NCT05950464: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recruiting
1
60
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Electrocardiography, ECG, EKG, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Tuvusertib, ATR Kinase Inhibitor M1774, M 1774, M-1774, M1774, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI), NRG Oncology
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Low Grade Endometrioid Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Low Grade Endometrioid Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
04/26
04/26
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
Canada, US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
Vyas, Yatin
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
64
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Michael Pulsipher, MD
SCID
08/26
08/26
Butowski, Nicholas A
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations
06/25
08/26
NCT05753007: A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Recruiting
2
36
US
Cannabidiol (CBD), Placebo
Mclean Hospital, University of California, San Francisco, Center for Medicinal Cannabis Research
Glioblastoma
09/25
09/25
DIET2TREAT, NCT05708352: A Phase 2 Study of the Ketogenic Diet Vs Standard Anti-cancer Diet Guidance for Patients with Glioblastoma in Combination with Standard-of-care Treatment

Recruiting
2
170
US
Keto Diet, Standard Anti-Cancer Diet
Cedars-Sinai Medical Center, National Cancer Institute (NCI)
Glioblastoma Multiforme
06/28
06/29
ST101-101, NCT04478279 / 2019-004213-13: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
125
Europe, US
ST101, Temozolomide, Radiation
Sapience Therapeutics
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
12/24
12/25
NCT06504381: DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Not yet recruiting
1/2
70
US
DB107-RRV, Toca 511, Vocimagene amiretrorepvec, DB107-FC, Toca FC, Extended-release 5-fluorocytosine, 5-fluorocytosine, Radiation Therapy (RT), Radiation Treatment, Temozolomide, Temozolomide (TMZ), Magnetic Resonance Imaging (MRI), MR, MRI, Surgical resection, Surgical tumor resection, Brain surgery
Nicholas Butowski, California Institute for Regenerative Medicine (CIRM)
High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
01/40
01/40
TNG908-C101, NCT05275478 / 2021-005605-27: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Active, not recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc., Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
NCT05370508: A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

Terminated
1/2
8
US
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS), Exablate Type 2.0
SonALAsense, Inc.
Recurrent GBM
06/24
07/24
NCT02022644: Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

Completed
1
18
US
nanoliposomal irinotecan, MM-398, ONIVYDE
University of California, San Francisco, Ipsen, National Cancer Institute (NCI)
High Grade Glioma
12/20
05/23
NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Terminated
1
14
US
IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127
Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI)
Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed
12/22
12/22
FRONTIER, NCT05303467: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Active, not recruiting
1
12
US
TheraSphere GBM, TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM)
Boston Scientific Corporation
Glioblastoma Multiforme, Recurrent Glioblastoma
12/24
06/25
NCT04656535: AB154 Combined with AB122 for Recurrent Glioblastoma

Recruiting
1
46
US
Zimberelimab, Domvanalimab, Placebo
Yale University, National Cancer Institute (NCI), Arcus Biosciences, Inc.
Glioblastoma
02/25
12/25
NCT05557292: RMC-5552 Monotherapy in Adult Subjects with Recurrent Glioblastoma

Recruiting
1
48
US
RMC-5552, mTORC1/4EBP1
Nicholas Butowski, Revolution Medicines, Inc., National Cancer Institute (NCI)
Glioblastoma, Recurrent Glioblastoma
12/25
12/25
Milhem, Mohammed
Neo-DREAM, NCT03567889 / 2021-003064-27: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients

Recruiting
3
186
Europe, US
Daromun, Surgery, Adjuvant therapy
Philogen S.p.A., Philogen S.p.A.
Melanoma Stage IIIB/C
06/24
06/26
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting
3
400
US
Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy
Replimune Inc.
Advanced Melanoma
01/29
08/34
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
NCT01879306: Abraxane Plus Bevacizumab Versus Ipilimumab as 1st Line Therapy for BRAFwt Metastatic Melanoma

Recruiting
2
176
US
paclitaxel albumin-stabilized nanoparticle formulation, ABI-007, nab paclitaxel, nab-paclitaxel, nanoparticle albumin-bound paclitaxel, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, ipilimumab, anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody, MDX-010, MDX-CTLA-4, monoclonal antibody CTLA-4, laboratory biomarker analysis, pharmacological study, pharmacological studies
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Stage IV Melanoma
06/15
 
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT04112641: NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

Active, not recruiting
2
48
US
Nicotinamide riboside, NIAGEN, Placebo capsules, Placebo
Donna Hammond, PhD
Chemotherapy-induced Peripheral Neuropathy
02/25
03/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
NCT02453191: TVEC and Preop Radiation for Sarcoma (4 ml Dose)

Completed
1/2
30
US
Talimogene Laherparepvec, Radiotherapy
University of Iowa, Amgen
Soft Tissue Sarcoma
01/19
03/23
NCT03508726: High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Completed
1/2
25
US
Ascorbate, Ascorbic Acid, Vitamin C, Pharmacological ascorbate
Mohammed Milhem, University of Iowa
Soft Tissue Sarcoma
06/22
06/24
NCT04599062: TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Active, not recruiting
1/2
8
US
Talimogene Laherparepvec, Radiotherapy
John Rieth, Amgen
Soft Tissue Sarcoma
02/23
11/24
DETERMINE, NCT06194929: Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
1/2
33
US
Defactinib, Avutometinib, Encorafenib
University of Utah, Verastem, Inc.
Melanoma
01/28
01/30
NCT06217536: Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas

Withdrawn
1/2
70
NA
Lurbinectedin, Zepzelca, Radiotherapy, Radiation therapy, Non-investigational surgery
University of California, San Francisco, Jazz Pharmaceuticals
Locally Advanced Soft Tissue Sarcoma
05/26
10/27
BT7480-100, NCT05163041: Study in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Active, not recruiting
1/2
200
Europe, US
BT7480, Nivolumab
BicycleTx Limited
Advanced Solid Tumor
09/25
12/25
NCT02959164: Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Completed
1b
36
US
Decitabine, Dacogen, Gemcitabine, Gemzar
Mohammed Milhem, Holden Comprehensive Cancer Center, University of Iowa
Pancreatic Ductal Adenocarcinoma, Sarcoma
09/19
10/20
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT03173976: Anti-Osteoclast Therapy As Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Active, not recruiting
1
17
US
Zoledronic Acid, Zometa®
Mohammed Milhem, Rising Tide Foundation
Chondrosarcoma
04/23
05/28
NCT05190315: Chlorpromazine and Standard of Care in Glioblastoma

Active, not recruiting
1
10
US
Chlorpromazine, Thorazine, Temozolomide, Temodar, Radiation Therapy
Mohammed Milhem
Glioblastoma Multiforme
04/23
04/25
CA101-001, NCT04423029 / 2021-000038-33: A Study of DF6002 Alone and in Combination With Nivolumab

Recruiting
1
438
Europe, US, RoW
DF6002, Nivolumab, Opdivo
Dragonfly Therapeutics
Solid Tumors
01/27
11/27
NCT04634227: Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

Recruiting
1
40
US
Ascorbate
University of Iowa, Mohammed Milhem, MBBS
Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
08/25
08/25
CFT8634-1101, NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Terminated
1
49
US
CFT8634
C4 Therapeutics, Inc.
Synovial Sarcoma, Soft Tissue Sarcoma
12/23
12/23
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
NCT04137900: Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Recruiting
1
499
US
TAB004, JS004, Toripalimab, TAB001, JS001
TopAlliance Biosciences, Shanghai Junshi Bioscience Co., Ltd., CTI Clinical Trial and Consulting Services
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
03/26
03/26
NCT06113809: Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)

Recruiting
1
8
US
Palbociclib, Pembrolizumab
John Rieth
Undifferentiated Pleomorphic Sarcoma
07/28
07/28
Uc, Ergun Y
LTAE-PD, NCT03808675: Aerobic Exercise in Parkinson's Disease

Completed
2/3
57
US
Aerobic walking, Usual care with PD specific health education
VA Office of Research and Development, University of Iowa
Parkinson's Disease
09/24
09/24
Vaena, Daniel
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
400
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
NCT04637594: Trying to Find the Correct Length of Treatment with Immune Checkpoint Therapy

Active, not recruiting
3
3
US
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma
06/24
09/30
SWOG S1937, NCT04579224: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Recruiting
3
184
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy
National Cancer Institute (NCI)
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
08/30
08/30
INCLINE-101, NCT05399654: A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
72
US, RoW
TAC-001
Tallac Therapeutics
Advanced or Metastatic Solid Tumors
01/26
05/26
Adams, Jennifer
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
Gerke, Alicia K
NCT01610843: Worldwide Sarcoidosis Research Study

Active, not recruiting
N/A
10000
US
Survey
University of Iowa, National Center for Research Resources (NCRR)
Sarcoidosis
02/25
02/25
Noiseux, Nicolas
NCT04297592: Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

Enrolling by invitation
4
4618
US
Cephalexin, Keflex, Doxycycline, Cefadroxil, Duricef
Mayo Clinic
Infections Joint Prosthetic, Overweight or Obesity, MSSA Colonization, MRSA, Chronic Kidney Diseases, Diabetes, Autoimmune Diseases, Inflammatory Disease, Tobacco Use
06/26
06/26
DEPOSITION, NCT03954314: - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery

Terminated
3
3242
Canada, RoW
Tranexamic Acid, Cyklokapron
Population Health Research Institute
Bleeding, Surgical Blood Loss, Seizures
11/23
11/23
PACES, NCT04045665 / 2021-005022-18: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting
3
3200
Europe, Canada, US
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center
Atrial Fibrillation, Stroke, Bleeding
06/25
06/25
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

Terminated
2
177
Europe, Canada, US, RoW
RMC-035, ROSgard, Placebo
Guard Therapeutics AB
Acute Kidney Injury
04/23
07/23
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery

Recruiting
2
161
Europe, Canada
RMC-035, Placebo
Guard Therapeutics AB
Kidney Injury Following Open-Chest Cardiac Surgery
10/25
10/25
ROMA, NCT03217006: Randomization of Single vs Multiple Arterial Grafts

Active, not recruiting
N/A
4300
Europe, Canada, Japan, US, RoW
Single arterial graft, Multiple arterial grafting
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), Canadian Institutes of Health Research (CIHR)
Coronary Artery Disease, Heart Diseases
06/27
01/30
LINKS, NCT02445443: LEGION Hinge Safety and Efficacy Study

Active, not recruiting
N/A
47
Europe, Canada, US, RoW
LEGION Hinge Knee System, LEGION HK
Smith & Nephew, Inc.
Knee Arthroplasty, Total
12/27
08/28
NCT05427370: The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

Recruiting
N/A
754
Europe, Canada, US, RoW
Revascularization by PCI, Revascularization by CABG
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR), Weill Medical College of Cornell University
Coronary Artery Disease, Heart Failure Systolic
04/29
12/29
NCT04124120: Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

Recruiting
N/A
2000
Europe, Canada, Japan, US, RoW
Single arterial graft, Multiple arterial grafting
Weill Medical College of Cornell University, New York Presbyterian Hospital, Sunnybrook Health Sciences Centre, Cedars-Sinai Medical Center, Columbia University, Duke University
Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
03/30
03/30
Bushnell, David
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
 

Download Options